Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sage Therapeutic Com (SAGE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Sage Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, February 22, 2018

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

SAGE : 162.37 (-0.75%)
Today's Research Reports on Stocks to Watch: Sarepta Therapeutics and Sage Therapeutics

NEW YORK, NY / ACCESSWIRE / February 12, 2018 / Sarepta shares closed in the red on Friday after the company's Essence study was halted in the U.K. Shares of Sage Therapeutics also closed down after announcing...

SRPT : 64.00 (+1.36%)
SAGE : 162.37 (-0.75%)
Stock Review for Biotech's Investors -- Sage Therapeutics, Sarepta Therapeutics, Sierra Oncology, and Sorrento Therapeutics

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on SAGE, SRPT, SRRA, and SRNE which can be accessed for free by signing up to www.wallstequities.com/registration....

SRNE : 8.75 (-3.31%)
SRPT : 64.00 (+1.36%)
SRRA : 2.90 (-2.03%)
SAGE : 162.37 (-0.75%)
Sage Therapeutics Prices Public Offering of Common Stock

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing...

JPM : 114.68 (-0.72%)
SAGE : 162.37 (-0.75%)
Sage Therapeutics Announces Proposed Public Offering of Common Stock

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

JPM : 114.68 (-0.72%)
SAGE : 162.37 (-0.75%)
Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder

--- Sage has received two Breakthrough Therapy designations for separate psychiatric drug candidates, reinforcing the Company's distinct approach to developing therapeutics to treat serious brain disorders...

SAGE : 162.37 (-0.75%)
Blog Exposure - Sage Therapeutics Declared Positive Results from Phase-1/2 Clinical Trial of SAGE-217 in Treatment of Insomnia

LONDON, UK / ACCESSWIRE / February 02, 2018 / Active-Investors.com has just released a free research report on Sage Therapeutics, Inc. (NASDAQ: SAGE). If you want access to this report all you need to...

SAGE : 162.37 (-0.75%)
Voyager Therapeutics Announces CEO Succession Plan for 2018

Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced plans during 2018 for Steven...

VYGR : 19.36 (+0.99%)
SAGE : 162.37 (-0.75%)
Sage Therapeutics Announces Positive Results from Placebo-Controlled Trial in a Model of Insomnia Demonstrating Activity on Sleep Parameters and Supporting Development of SAGE-217 as Potential Treatment for Sleep Disorders

--- Secondary endpoint measures demonstrated clear dose response with statistical significance in total sleep time and time spent awake after sleep onset -

SAGE : 162.37 (-0.75%)
3 Small-Cap ETFs for Your Portfolio

U.S. small cap ETFs pick up on positive political developments.

IJR : 77.33 (+0.35%)
BR : 98.78 (-0.22%)
CHE : 254.56 (-0.28%)
FANG : 123.88 (-1.01%)
BLUE : 213.35 (+2.25%)
XPO : 91.43 (-0.62%)
SAGE : 162.37 (-0.75%)
CMD : 114.53 (+0.07%)
VB : 148.35 (+0.24%)
IWM : 153.34 (+0.35%)
NKTR : 83.43 (+1.57%)
3 Small-Cap ETFs for Your Portfolio

U.S. small cap ETFs pick up on positive political developments.

IJR : 77.33 (+0.35%)
BR : 98.78 (-0.22%)
CHE : 254.56 (-0.28%)
FANG : 123.88 (-1.01%)
BLUE : 213.35 (+2.25%)
XPO : 91.43 (-0.62%)
SAGE : 162.37 (-0.75%)
CMD : 114.53 (+0.07%)
VB : 148.35 (+0.24%)
IWM : 153.34 (+0.35%)
NKTR : 83.43 (+1.57%)
Sage Therapeutics to Provide Pipeline Update at J.P. Morgan Healthcare Conference and Outline Key 2018 Initiatives to Support Planned Evolution to a Fully-Integrated Commercial Biopharmaceutical Company

--- 2018 strategy focuses on continued R&D innovation, pipeline expansion and commercialization plans for new classes of CNS therapeutics -

JPM : 114.68 (-0.72%)
SAGE : 162.37 (-0.75%)
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that,...

SAGE : 162.37 (-0.75%)
Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

JPM : 114.68 (-0.72%)
SAGE : 162.37 (-0.75%)
Pre-Market Technical Scan on Biotech Equities -- Amicus Therapeutics, Radius Health, Sage Therapeutics, and Pulmatrix

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on FOLD, RDUS, SAGE, and PULM which can be accessed for free by signing up to www.wallstequities.com/registration....

FOLD : 15.17 (-4.17%)
PULM : 1.48 (-3.27%)
RDUS : 37.91 (-1.71%)
SAGE : 162.37 (-0.75%)
Sage Therapeutics Soars: Stock Adds 7.1% in Session

Sage Therapeutics (SAGE) was a big mover last session, as the company saw its shares rise more than 7% on the day.

COLL : 25.90 (+2.13%)
SAGE : 162.37 (-0.75%)
Today's Research Reports on Stocks to Watch: Sage Therapeutics and Nektar Therapeutics

NEW YORK, NY / ACCESSWIRE / December 8, 2017 / Sage Therapeutics headed higher on Thursday and hit a brand new high after announcing that its depressive disorder MDD treatment SAGE-217 had seen positive...

SAGE : 162.37 (-0.75%)
NKTR : 83.43 (+1.57%)
Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

SAGE : 162.37 (-0.75%)
Sage Therapeutics, Dollar General jump; LendingClub tumbles

NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday:

EW : 133.82 (-0.64%)
SAGE : 162.37 (-0.75%)
TLRD : 23.31 (-0.04%)
Sage Therapeutics Reports Positive Top-line Results from Phase 2 Placebo-Controlled Trial of SAGE-217 in Major Depressive Disorder

--- Well-tolerated and demonstrated highly statistically significant mean reduction in the HAM-D score compared to placebo at 15 days (p

SAGE : 162.37 (-0.75%)

Van Meerten Stock Picks

Market trading below its 150 DMA
Summary52% of the market is trading below its 150 DMA.
IWV +0.12
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 +0.18%) this morning are up +0.17% at a 1 -1 /2 week high and European stocks are up +0.74% at a 1-week high. Strength in crude oil and metals prices has fueled a rally in energy and mining... Read More

Chart of the Day

Abiomed (ABMD) is the Barchart Chart of the Day.  The medical instrument company has a Trend Spotter buy signal, a Weighted Alpha o 139.67+ and gained 132.53% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures closed the Friday session with fractional losses, as nearby March was 1.52% higher on the week. The USDA reported a private export sale of 116,000 MT of 17/18 corn to Japan through their daily reporting system this morning. Export commit...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.